ThePigSite.com - news, features, articles and disease information for the swine industry

News

New Zoetis Vaccine Protects Against PCV2 and M. Hyo

16 November 2016
Zoetis

UK - A new one-bottle, one-dose bivalent vaccine that helps protect pigs against the effects of both porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo) is now available from Zoetis. Suvaxyn Circo+MH RTU provides active immunisation against the economically important diseases caused by PCV2 and enzootic pneumonia.

“Respiratory disease from M. hyo, and the effects of PCV2, can be devastating to pig herds through reduced growth rates, poor feed efficiency, increased mortality and extended time to market,” said UK Pig and Poultry Business Unit Director Ben Lacey. “That is why we let science lead the way in developing an effective vaccine in one convenient bottle that is fit for the 21st Century.

“This is a true bivalent vaccine built from the ground up and not just two existing products mixed together,” he added, “aspects of human vaccine technology have also been applied to the manufacturing process.

“In particular, extraneous proteins that can affect efficacy and safety are removed from the new vaccine; a unique whole-virus vaccine approach is taken with the PCV2 antigen to elicit a more complete immune response; and the M. hyo portion is filtered to reduce PCV2 antibodies (present in the pig serum required to culture M. Hyo) which could bind to PCV2 antigen in the vaccine, reducing efficacy of a combined product; the filtration process also purifies the M. hyo, resulting in a high level of membrane antigens vital for a targeted immune response.”

The adjuvant MetaStim completes the package; it stimulates both humoral and cellular immunity and has proven efficacy in vaccines such as Suvaxyn MH-One. MetaStim does not contain any mineral oil, which means reduced risk of serious injury in case of accidental self-injection, but this also limits the effects of local inflammation at the injection site and has contributed to the complete absence of anaphylactic reactions in safety trials.

Clinical trials have shown that Suvaxyn Circo+MH RTU reduces faecal shedding caused by PCV2 infection, as well as reducing the viral load in blood and lymphoid tissues. It also reduces lung lesions caused by M. hyo infection. This protection is achieved from a single 2ml dose that can be given from three weeks of age. The onset of immunity to both PCV2 and M. hyo is fully effective three weeks after vaccination.

Additional benefits of using one-shot vaccination include reducing stress for the pigs and decreasing labour time required for vaccination, as only a single injection is required.
Suvaxyn Circo+MH RTU is available now in pack sizes of 50 and 125 doses.

Suvaxyn Circo+MH RTU Emulsion for Injection for Pigs contains inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein and inactivated Mycoplasma hyopneumoniae, strain P-5722-3. For active immunisation of pigs against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae. POM-V

For further information please see the product’s SPC or please contact your veterinary surgeon or Zoetis UK Limited, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS. www.zoetis.co.uk Customer Support: 0845 300 8034. Use medicines responsibly (www.noah.co.uk/responsible). Date of preparation: October 2016. AH639/16

ThePigSite News DeskRead more Zoetis news here


Share This

News By

Related News

More News

Our Sponsors

Partners


Seasonal Picks

The Commuter Pig Keeper - 5m Books